Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response

Vaccine
Kenneth FlanaganHoward L Kaufman

Abstract

Secondary lymphoid chemokine (SLC) attracts mature dendritic cells (DCs) and naïve T cells. Co-localization of these cells within local tumor environments may enhance the induction of tumor-specific T cells. However, the presence of danger signals or other DC maturation signals are required to optimize T-cell priming. We hypothesized that expression of SLC in vaccinia virus would provide local chemokine delivery and adjuvant factors. A recombinant vaccinia virus expressing murine SLC (rVmSLC) was constructed and characterized. SLC expression was confirmed by Western blot analysis and functional activity was determined by in vitro chemotaxis assay. Supernatants from rVmSLC-infected cells attracted CD4 T cells, and also induced the migration of CD8 T cells and DCs. Although poxviruses are known to express several chemokine-binding proteins, systemic injection of rVmSLC was well tolerated in mice up to a dose of 1 x 10(7) pfu and did not significantly alter vaccinia-specific T-cell immunity. Local injection of rVmSLC into established tumors derived from the murine colon cancer line, CT26, resulted in enhanced infiltration of CD4 T cells, which correlated with inhibition of tumor growth. The central role of CD4 T cells was further ...Continue Reading

References

Oct 15, 1996·Proceedings of the National Academy of Sciences of the United States of America·B Moss
Feb 21, 1998·Proceedings of the National Academy of Sciences of the United States of America·M D GunnL T Williams
Jan 6, 2000·The Journal of Experimental Medicine·H R LüttichauT W Schwartz
Jun 3, 2000·Annual Review of Immunology·F SallustoA Lanzavecchia
Oct 12, 2000·Proceedings of the National Academy of Sciences of the United States of America·H XiaoK T Jeang
Nov 9, 2000·Proceedings of the National Academy of Sciences of the United States of America·S A LutherJ G Cyster
Feb 28, 2001·Cancer Immunology, Immunotherapy : CII·D A ArenbergR M Strieter
Mar 20, 2002·Cytokine & Growth Factor Reviews·Alain P Vicari, Christophe Caux
Mar 27, 2002·Nature Reviews. Immunology·Bernhard HomeyAlbert Zlotnik
Jun 19, 2002·Cancer Immunology, Immunotherapy : CII·Liviu V TituJohn Greenman
Jun 26, 2002·Annals of the New York Academy of Sciences·Polly Matzinger
Sep 13, 2002·Immunology and Cell Biology·Shaun R McColl

❮ Previous
Next ❯

Citations

Sep 6, 2012·Immunotherapy·Elham Mohit, Sima Rafati
Mar 9, 2012·Advances in Virology·Mark S FergusonYaohe Wang
Aug 25, 2007·Cancer Metastasis Reviews·Simi Ali, Gwendal Lazennec
Sep 25, 2007·Pharmaceutical Research·Jian-Qing GaoShinsaku Nakagawa
Jun 10, 2006·Hematology/oncology Clinics of North America·Andrew EisenbergerHoward L Kaufman
Mar 3, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Barrett J Rollins
Jun 15, 2007·International Reviews of Immunology·Robert C Ward, Howard L Kaufman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.